News

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.

The SVR rates remained consistently high after the investigators conducted a subgroup analysis stratified by genotype, treatment duration, fibrosis stage, and concomitant medications.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

David Rosmarin, MD, reviews a quintet of promising agents advancing in late stages while at RAD 2023.

The geometric mean duration of single-occupancy room isolation was 1.8 days in the mPOCT group, compared to 2.6 days in the control group.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.

The biosimilars month in review highlights the positive safety and efficacy data of 3 biosimilars used to treat rheumatic diseases, gastroenterologists discuss the risks and benefits of prescribing biosimilars to their patients, and physicians emphasize the importance of patient education.

Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

According to the study, gay and bisexual adolescents show higher rates of sleep issues and sleep disturbances.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.

The extended-release injectable suspension treatment represents the first subcutaneous, long-acting formulation of risperidone.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

Announced on May 1, the CRL from the FDA expressed concerns related to manufacturing control strategy, but did not express concern related to clinical data submitted as part of the NDA package for TransCon PTH.

In this interview segment, Silverberg discussed some of the major takeaways from his Revolutionizing Atopic Dermatitis presentation on eligibility for systemic treatments.

An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.

Interim analysis suggest the JAK inhibitor may become a breakthrough treatment for chronic hand dermatitis—a condition currently without a marketed drug.

Post-hoc data from the phase 3 ADhere trial shows a lebrikizumab regimen may help patients with atopic dermatitis achieve skin clearance they could not with dupilumab.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

During this interview segment, Singh spoke on the ways in which dermatologists may help infants manage atopic dermatitis, as well as her outlook on the future of treatment.

In this interview, Singh described the major takeaways from her presentation on allergy testing for infants which she gave at the Revolutionizing Atopic Dermatitis conference.

A Brazil cross-sectional analysis suggests chronic pruritus is even more common—and burdensome—in atopic dermatitis patients than previously believed.